Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Pfreundschuh M, et al. Among authors: kloess m. Blood. 2004 Aug 1;104(3):626-33. doi: 10.1182/blood-2003-06-2094. Epub 2004 Feb 24. Blood. 2004. PMID: 14982884 Free article. Clinical Trial.
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Pfreundschuh M, et al. Among authors: kloess m. Blood. 2004 Aug 1;104(3):634-41. doi: 10.1182/blood-2003-06-2095. Epub 2004 Mar 11. Blood. 2004. PMID: 15016643 Free article. Clinical Trial.
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma.
Glass B, Kloess M, Bentz M, Schlimok G, Berdel WE, Feller A, Trümper L, Loeffler M, Pfreundschuh M, Schmitz N; German High-Grade Non-Hodgkin Lymphoma Study Group. Glass B, et al. Among authors: kloess m. Blood. 2006 Apr 15;107(8):3058-64. doi: 10.1182/blood-2005-04-1570. Epub 2005 Dec 29. Blood. 2006. PMID: 16384932 Free article. Clinical Trial.
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Wunderlich A, et al. Among authors: kloess m. Ann Oncol. 2003 Jun;14(6):881-93. doi: 10.1093/annonc/mdg249. Ann Oncol. 2003. PMID: 12796026 Free article. Clinical Trial.
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B; German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL). Schmitz N, et al. Among authors: kloess m. Cancer. 2006 Jan 1;106(1):136-45. doi: 10.1002/cncr.21588. Cancer. 2006. PMID: 16331635 Free article. Clinical Trial.
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N. Boehme V, et al. Among authors: kloess m. Ann Oncol. 2007 Jan;18(1):149-157. doi: 10.1093/annonc/mdl327. Epub 2006 Oct 3. Ann Oncol. 2007. PMID: 17018708 Free article. Clinical Trial.
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.
Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, Vonhof S, Bickeböller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nürnberg P, Pfreundschuh M, Trümper L, Brockmöller J, Hasenfuss G. Wojnowski L, et al. Among authors: kloess m. Circulation. 2005 Dec 13;112(24):3754-62. doi: 10.1161/CIRCULATIONAHA.105.576850. Epub 2005 Dec 5. Circulation. 2005. PMID: 16330681
Moral injury in civilians: associations with trauma exposure, PTSD, and suicide behavior.
Fani N, Currier JM, Turner MD, Guelfo A, Kloess M, Jain J, Mekawi Y, Kuzyk E, Hinrichs R, Bradley B, Powers A, Stevens JS, Michopoulos V, Turner JA. Fani N, et al. Among authors: kloess m. Eur J Psychotraumatol. 2021 Sep 28;12(1):1965464. doi: 10.1080/20008198.2021.1965464. eCollection 2021. Eur J Psychotraumatol. 2021. PMID: 34603635 Free PMC article.